The HARMONY Alliance is a public-private European Network established in 2017, which currently includes 53 Partners and 43 associated members from 17 countries. One of HARMONY's goals is to use Big Data to improve understanding and treatment of hematological malignancies.
One of HARMONY's work packages is focused on defining core outcome set (COS) - outcomes that are relevant to each malignancy included in HARMONY.
This study will define the core outcome set in multiple myeloma (MM).
Different stakeholder will provide their expert feedback in a Delphi survey and rank different outcomes according to their importance. The different stakeholder groups include clinicians, patients and patient advocates and members of EFPIA (European Federation of Pharmaceutical Industries and Associations). A future use of COS can improve the comparability of clinical trials and the consistency of reporting. Therefore COS can help to ensure appropriate outcomes are measured in future clinical trials.
Lars Bullinger, WP 2 Leader, HARMONY Partner Charit? Berlin
Renate Schulze-Rath, WP 2 Leader, HARMONY Partner Bayer
HARMONY Alliance, Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
- COS for clinical trials or clinical research
- COS for practice
- Consensus meeting
- Delphi process
Delphi process, 3 rounds, and a final Consensus meeting